Breaking News on Global Pharmaceutical Technology & Manufacturing

Lonza to make heart failure gene therapy for Renova at Houston site

11-Feb-2016 - Lonza will make a candidate heart failure gene therapy for Renova Therapeutics under the second biomanufacturing deal it has signed this week.

GSK is latest to assess VBI Vaccines' biologic stability tech after Sanofi

10-Feb-2016 - GSK will test a stability enhancement technology developed by VBI Vaccines in a deal announced this week.

Juniper to reformulate unpleasant tasting PharmAust cancer drug

08-Feb-2016 - Up to 90% of new chemical entities having properties that make them a challenge to successfully formulate, says Juniper Pharmaceuticals which has won a reformulation and manufacturing contract from PharmAust.

Sandoz teams with delivery tech firm MedinCell to get under the skin of cancer

04-Feb-2016 - Novartis subsidiary Sandoz will commercialise small and large molecule injectables using French delivery tech firm MedinCell’s subcutaneous controlled release platform.

MannKind sheds light on new $100m inhaled formulation partner

04-Feb-2016 - MannKind has spoken about Receptor Life Science, a newly-formed company which last month licensed the Technosphere inhaled delivery platform from the struggling firm.

Albumedix buys Eleven's half-life boosting albumin assets

29-Jan-2016 - Novozymes’ albumin technologies division Albumedix has bought Eleven Biotherapeutics’ half-life extension assets.

Could drug-loaded dental implants offer pain-free chronic med delivery?

27-Jan-2016 - Drug-loaded dental implants which release payload on-demand could alleviate invasive procedures associated with chronic diseases, scientists suggest.

Recipharm raises $32m to fund Nitin deal

27-Jan-2016 - Recipharm has raised SEK276m ($32m) to part finance the acquisition of a majority stake in Indian CMO Nitin Life Sciences that it announced in October.

Austrianova rolls out cell banking and fill finish services

27-Jan-2016 - Austrianova has launched cell banking and fill finish services for cell therapy developers at its facility in Singapore.

Re-engineering the malaria parasite for drug delivery

26-Jan-2016 - An associate professor at MIT is re-engineering the malaria parasite to act as vehicle for drug delivery.

No Zika vaccine in sight, but modified yellow fever virus vector could speed development

25-Jan-2016 - A Zika vaccine is a long way off according to a UK academic who suggested vaccines for related viruses could be used as delivery vectors to accelerate development.

Catalent continues to scout acquisitions and licensing in 2016

25-Jan-2016 - Catalent will pursue strategic acquisitions and licensing in 2016, said VP Marketing & Strategy Elliott Berger, noting growth areas include complex delivery technologies and specialised logistics.

$4m grant not to be sniffed at as Mucosis looks to advance intranasal RSV vaccine

21-Jan-2016 - Mucosis has been awarded a Wellcome Trust grant of €3.7m ($4m) to help develop a Respiratory Syncytial Virus (RSV) vaccine using its intranasal delivery platform.

Johnson Matthey expands Cambridge catalysis facility

21-Jan-2016 - Johnson Matthey has expanded its UK biocatalysis R&D operations in response to growing drug industry demand.

New Novozymes subsidiary Albumedix to develop its own drug pipeline says CEO

20-Jan-2016 - Novozymes’ new subsidiary Albumedix has announced its intention to develop biobetters and says the first candidate could be in Phase I trials by 2019.

Centauri buys nucleotide tech to develop alternatives to antibiotics

18-Jan-2016 - UK-based biotech Centauri Therapeutics has acquired a “programmable immunity” aptamer technology from Altermune Technologies.

‘Lightning drug’ to advance personalized medicine

18-Jan-2016 - Researchers have found a way to illuminate and track a common cancer drug, a method which shows promise in advancing personalized medicine.

Liquid-metal 'nano-terminators' seek and destroy

14-Jan-2016 - A new liquid-metal drug delivery method shows promise in enhancing the effectiveness of drugs.

‘Unshackled’ from Sanofi, MannKind turns to Technosphere and Twitter

14-Jan-2016 - MannKind says its Technosphere delivery platform could yield short-term cash and drive long-term growth.

MannKind withdraws job offer a week after Insulet's ex-CEO was set to start

12-Jan-2016 - Insulet CEO Duane DeSisto will no longer be taking the top job at MannKind Corporation after the inhaled insulin developer withdrew the offer.

Allergan buys toxin delivery tech firm, boosts Botox portfolio

11-Jan-2016 - Allergan has acquired neurotoxin company Anterios for $90m (€83m).

Fresenius Kabi moves into prefilled syringe space through BD Rx buy

11-Jan-2016 - Fresenius Kabi has moved into the prefilled syringe space by acquiring Becton, Dickinson and Company’s injectables business and US manufacturing plant.

News in brief

Amgen secures a wearable injector deal with Unilife

07-Jan-2016 - After securing partnerships with AbbVie and Sanofi, Unilife has announced another exclusive agreement for a wearable injector device with Amgen.

Sanofi’s ‘conflicted’ handling of Afrezza stunted inhaled insulin R&D, says Dance CEO

07-Jan-2016 - Despite Sanofi’s “conflicted” management and subsequent abandonment of Afrezza, the market opportunity for inhaled insulin is still huge, according to Dance Biopharm's CEO.

Down but not out: MannKind sees positive in Sanofi’s Afrezza exit

06-Jan-2016 - Sanofi has abandoned Afrezza less than a year after its launch, but the future of the inhaled insulin product is secure according to developer MannKind.

Key Industry Events


Access all events listing

Our events, Shows & Conferences...